Vinciane Rebours
Prof Vinciane Rebours is an expert in Gastroenterology at Beaujon Hospital (France). As of October 2026, ScienceLeadR ranks Vinciane Rebours in the top 1% of experts worldwide for Pancreatitis and Pancreatic Diseases. Vinciane Rebours has authored 337 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 2 of them ongoing. SLR score: 949 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Oncology - Surgery - Hepatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 337
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Comparison of endoscopic and radiologic drainage for symptomatic postoperative pancreatic fistula-associated collections after distal pancreatectomy. PMID 42864456 — drainage, stents, fistula, endoscopy, therapeutics, pancreatic fistula, pancreatectomy | Surg Endosc | 2026 | 0 |
| Aetiology-Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO-PEI Registry. PMID 42827323 — registries, pancreatic neoplasms, pancreatitis, chronic, neoplasms, signs and symptoms, pancreatitis, enzymes, therapeutics, gastrointestinal diseases, pancreatectomy | United European Gastroenterol J | 2026 | 0 |
| Clinical application of digital pathology in small intestinal neuroendocrine tumours: proposal of a new G0 category. PMID 42801155 — telepathology, pathology, neoplasm metastasis | Endocr Oncol | 2026 | 0 |
| Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. PMID 42507965 — intelligence, pancreatic neoplasms, neoplasms, drug therapy, biomarkers, chemotherapy, adjuvant, deep learning, histology, therapeutics, medical oncology, learning, artificial intelligence, chemotherapy | J Clin Oncol Top journal | 2026 | 2 |
| Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. PMID 42334072 — pancreatic neoplasms, neoplasms, interleukin-6, cohort studies, immune system | Int J Cancer | 2026 | 0 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| French National Cohort of Patients With PRSS1 Mutations NCT07413029 — genes, pancreatitis, history, mutation | N/A | Recruiting | 2024 |
| A Phase 3 Study of Obexelimab in Patients With IgG4 Related Disease NCT05662241 — cells, safety, immunoglobulin g4-related disease, immunoglobulins, antibodies, monoclonal, b-lymphocytes | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map